Evaluating Adaptive Dispenser Initiation Protocols for MySafeRx During Post-detox Buprenorphine Treatment- a Pilot Study

NACompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

July 13, 2020

Primary Completion Date

August 26, 2021

Study Completion Date

September 30, 2021

Conditions
Opioid-use Disorder
Interventions
OTHER

MySafeRx Inspire Plus

The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.

OTHER

MySafeRx Inspire Flex

The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. Based on clinical need, the participant may be assigned an electronic pill dispenser for the duration of the study by their clinical team.

Trial Locations (1)

33610

ACTS Adult Addiction Receiving Facility (AARF), Tampa

All Listed Sponsors
collaborator

Cambridge Health Alliance

OTHER

lead

University of South Florida

OTHER

NCT04449744 - Evaluating Adaptive Dispenser Initiation Protocols for MySafeRx During Post-detox Buprenorphine Treatment- a Pilot Study | Biotech Hunter | Biotech Hunter